Directed share issue in Faron Pharmaceuticals Oy (FI) – EUR 14.0 million

Carnegie acted as sole global co-ordinator and sole bookrunner in the Nordic placing. The Company raised aggregate gross proceeds of EUR 14.0 million in two tranches of which EUR 10.9 million was attributable to the Nordic placing and EUR 3.1 million to the UK placing, respectively. Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. April 2020.